
Peter Mac scientists have developed a simple blood test that can show which men with the most aggressive type of prostate cancer should respond to conventional therapy, and those who need other options.
From as little as 10ml of blood, the test can simultaneously profile the circulating DNA and RNA which is shed by cancer cells, offering important insights into the make-up of the cancer and treatments most likely work.
Nearly 20,000 men are diagnosed with prostate cancer every year in Australia, making up a quarter of all male cancer diagnoses, and mCRPC is the most aggressive form accounting for over 3000 deaths from this disease every year.
Metastatic prostate cancer has spread beyond the prostate, and it is “castration-resistant” if progression continues despite the patient starting therapy that deprives the cancer of androgen hormones, such as testosterone.
“While advances in therapeutic strategies have significantly improved quantity and quality of life for men with mCRPC, there remains a pressing need to find predictive and prognostic biomarkers,” explains A/Prof Arun Azad, senior author on the study and medical oncologist at Peter Mac.
“These blood tests, also called liquid biopsies, have emerged as a minimally-invasive alternative to conventional biopsy for interrogating the prostate tumour genome.
“Liquid biopsies have demonstrated strong congruence with tumour biopsies, whilst simultaneously encapsulating the genomic complexity often seen in mCRPC.”
In this study, published in the journal European Urology, researchers applied Predicine’s cell-free DNA and cell-free RNA next generation sequencing liquid biopsy technology to detect whether changes to the Androgen Receptor (AR) gene have occurred within mCRPCs.
They used this to test the blood of Australian men with mCRPC prior to treatment, accurately detecting some form of AR alteration in over half of patients.
“We found that abnormalities in the AR gene detected in the blood of men with advanced prostate cancer were associated with poor responses to available drug treatments and reduced survival,” says A/Prof Azad.
This information could be used to better guide treatment of advanced prostate cancer.”
“A simple test to detect AR abnormalities would help doctors determine optimal treatment selection, better design innovative clinical trials, and aid in discussions with patients and caregivers around realistic and expected outcomes.
The study results were further validated in a second cohort of prostate cancer patients in the United States.
The new liquid biopsy test from Predicine is also more informative than previous tests as it analyses two types of genetic material – DNA and RNA – to give a more in-depth and accurate insight into AR abnormalities within the cancer.
Source – Peter Mac
Fettke H, Kwan EM, Docanto MM, et al. (2020) Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol [published online ahead of print]. [abstract]
Peter Mac scientists have developed a simple blood test that can show which men with the most aggressive type of prostate cancer should respond to conventional therapy, and those who need other options.
From as little as 10ml of blood, the test can simultaneously profile the circulating DNA and RNA which is shed by cancer cells, offering important insights into the make-up of the cancer and treatments most likely work.
Nearly 20,000 men are diagnosed with prostate cancer every year in Australia, making up a quarter of all male cancer diagnoses, and mCRPC is the most aggressive form accounting for over 3000 deaths from this disease every year.
Metastatic prostate cancer has spread beyond the prostate, and it is “castration-resistant” if progression continues despite the patient starting therapy that deprives the cancer of androgen hormones, such as testosterone.
In this study, published in the journal European Urology, researchers applied Predicine’s cell-free DNA and cell-free RNA next generation sequencing liquid biopsy technology to detect whether changes to the Androgen Receptor (AR) gene have occurred within mCRPCs.
They used this to test the blood of Australian men with mCRPC prior to treatment, accurately detecting some form of AR alteration in over half of patients.
The study results were further validated in a second cohort of prostate cancer patients in the United States.
The new liquid biopsy test from Predicine is also more informative than previous tests as it analyses two types of genetic material – DNA and RNA – to give a more in-depth and accurate insight into AR abnormalities within the cancer.
Source – Peter Mac
Fettke H, Kwan EM, Docanto MM, et al. (2020) Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol [published online ahead of print]. [abstract]
Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
Peter Mac scientists have developed a simple blood test that can show which men with the most aggressive type of prostate cancer should respond to conventional therapy, and those who need other options.
From as little as 10ml of blood, the test can simultaneously profile the circulating DNA and RNA which is shed by cancer cells, offering important insights into the make-up of the cancer and treatments most likely work.
Nearly 20,000 men are diagnosed with prostate cancer every year in Australia, making up a quarter of all male cancer diagnoses, and mCRPC is the most aggressive form accounting for over 3000 deaths from this disease every year.
Metastatic prostate cancer has spread beyond the prostate, and it is “castration-resistant” if progression continues despite the patient starting therapy that deprives the cancer of androgen hormones, such as testosterone.
In this study, published in the journal European Urology, researchers applied Predicine’s cell-free DNA and cell-free RNA next generation sequencing liquid biopsy technology to detect whether changes to the Androgen Receptor (AR) gene have occurred within mCRPCs.
They used this to test the blood of Australian men with mCRPC prior to treatment, accurately detecting some form of AR alteration in over half of patients.
The study results were further validated in a second cohort of prostate cancer patients in the United States.
The new liquid biopsy test from Predicine is also more informative than previous tests as it analyses two types of genetic material – DNA and RNA – to give a more in-depth and accurate insight into AR abnormalities within the cancer.
Source – Peter Mac
Fettke H, Kwan EM, Docanto MM, et al. (2020) Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol [published online ahead of print]. [abstract]
Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
Stay Connected
Submit a Post to the Blog
Recent Posts
Subscribe to the RNA-Seq Blog
RNA-Seq Products & Services